Topic: skin cancer

Regeneron has lost its edge in antibody development, so its growth potential may be limited, Analysts at SVBLeerink argue in a new report.

They say a picture’s worth a thousand words, and Sanofi and Regeneron are using that exchange rate to their advantage with Libtayo.

Sanofi and Regeneron’s Libtayo is two for two in the last two days—at winning over key European regulatory and reimbursement bodies, that is.

Merck’s latest Keytruda OK isn’t a huge one for the New Jersey pharma. But it’s a big deal for Bavencio drugmakers Pfizer and Merck KGaA.

Sanofi and Regeneron's Libtayo may be the sixth in its class to launch, but it already has something not all its rivals do: a market all to itself.

Merck is getting ready to take on Pfizer and Merck KGaA’s Bavencio in a rare form of skin cancer, and the FDA just sped up the showdown.

Why does Sanofi think it can carve a niche in lung cancer when it’ll be sixth to market—and Merck’s Keytruda is far, far ahead?

Pfizer and Merck KGaA’s Bavencio, which won an FDA nod for Merkel cell carcinoma in March, has now been approved in Europe to treat that cancer.

Pfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor avelumab—but first with to target a rare, aggressive form of skin cancer.

SkinJect, a Pittsburgh-based device company, said it reached a deal with the University of Pittsburgh to license a minimally invasive treatment for common forms of nonmelanoma skin cancer, basal cell and squamous cell carcinoma.